Literature DB >> 26725962

Pulmonary function and cardiac stress test after multimodality treatment of esophageal cancer.

Gabriella Alexandersson von Döbeln1, Magnus Nilsson2, Gunnar Adell3, Gjermund Johnsen4, Ingunn Hatlevoll5, Jon Tsai2, Lars Lundell2, Mikael Lund2, Pehr Lind6.   

Abstract

PURPOSE: Curative treatment of esophageal cancer is accompanied by frequent and sometimes severe side effects. However, prospectively collected data on side effects are scarce. The aim of this study was to evaluate if pulmonary function and exercise capacity were affected in the acute setting after neoadjuvant treatment and if there were long-lasting effects after neoadjuvant treatment and surgery. We also aimed to investigate whether the addition of radiation therapy to chemotherapy would aggravate side effects. METHODS AND MATERIALS: A cohort of 97 patients enrolled in the randomized NeoRes trial was used for the present analysis. The patients had been randomized to receive 3 cycles of cisplatin and fluorouracil with or without concurrent radiation therapy to 40 Gy. A cardiac stress test on a stationary bicycle and a spirometry were performed before and after neoadjuvant treatment and 1 to 2 years later after surgery provided that the cancer had not recurred.
RESULTS: We found impairment in pulmonary function measured as vital capacity and forced expiratory volume in 1 second and a decrease in exercise capacity after neoadjuvant treatment and 1 to 2 years later after surgery. We did not detect any differences between patients treated with chemoradiation therapy and those treated with chemotherapy alone.
CONCLUSIONS: Multimodality treatment of esophageal cancer caused short-term and lasting impairments in pulmonary function and exercise capacity. The reductions were not aggravated by the addition of radiation therapy to neoadjuvant chemotherapy.
Copyright © 2015 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26725962     DOI: 10.1016/j.prro.2015.10.015

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  6 in total

1.  Physical decline and its implications in the management of oesophageal and gastric cancer: a systematic review.

Authors:  Linda O'Neill; Jonathan Moran; Emer M Guinan; John V Reynolds; Juliette Hussey
Journal:  J Cancer Surviv       Date:  2018-05-23       Impact factor: 4.442

2.  Inspiratory muscle training attenuates irradiation-induced diaphragm dysfunction.

Authors:  Li-Ying Wang; Pei-Yu Yang; Yu-Jen Chen; Huey-Dong Wu; Yi-Hsuan Huang; Chen-Hsi Hsieh
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

3.  Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance.

Authors:  Emer M Guinan; S L Doyle; A E Bennett; L O'Neill; J Gannon; J A Elliott; J O'Sullivan; J V Reynolds; J Hussey
Journal:  Support Care Cancer       Date:  2017-12-02       Impact factor: 3.603

4.  Cardiorespiratory Comorbidity and Postoperative Complications following Esophagectomy: a European Multicenter Cohort Study.

Authors:  F Klevebro; J A Elliott; A Slaman; B D Vermeulen; S Kamiya; C Rosman; S S Gisbertz; P R Boshier; J V Reynolds; I Rouvelas; G B Hanna; M I van Berge Henegouwen; S R Markar
Journal:  Ann Surg Oncol       Date:  2019-06-10       Impact factor: 5.344

5.  Cardiovascular Burden and Adverse Events in Patients With Esophageal Cancer Treated With Chemoradiation for Curative Intent.

Authors:  Mette Marie A Søndergaard; Marianne Nordsmark; Kirsten M Nielsen; Steen H Poulsen
Journal:  JACC CardioOncol       Date:  2021-12-21

6.  Effects of high-intensity exercise training on physical fitness, quality of life and treatment outcomes after oesophagectomy for cancer of the gastro-oesophageal junction: PRESET pilot study.

Authors:  C Simonsen; S Thorsen-Streit; A Sundberg; S S Djurhuus; C E Mortensen; C Qvortrup; B K Pedersen; L B Svendsen; P de Heer; J F Christensen
Journal:  BJS Open       Date:  2020-08-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.